4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Activated microglia mitigate Aβ-associated tau seeding and spreading

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In this paper, we evaluate whether elimination or repopulation of microglia affects Aβ-induced tau seeding and spreading. Elimination of microglia increases NP-tau seeding and spreading. Interestingly, repopulated microglia cluster around amyloid plaques, exhibit a homeostatic gene expression signature, and also result in elevated NP-tau seeding and spreading.

          Abstract

          In Alzheimer’s disease (AD) models, AD risk variants in the microglial-expressed TREM2 gene decrease Aβ plaque–associated microgliosis and increase neuritic dystrophy as well as plaque-associated seeding and spreading of tau aggregates. Whether this Aβ-enhanced tau seeding/spreading is due to loss of microglial function or a toxic gain of function in TREM2-deficient microglia is unclear. Depletion of microglia in mice with established brain amyloid has no effect on amyloid but results in less spine and neuronal loss. Microglial repopulation in aged mice improved cognitive and neuronal deficits. In the context of AD pathology, we asked whether microglial removal and repopulation decreased Aβ-driven tau seeding and spreading. We show that both TREM2 KO and microglial ablation dramatically enhance tau seeding and spreading around plaques. Interestingly, although repopulated microglia clustered around plaques, they had a reduction in disease-associated microglia (DAM) gene expression and elevated tau seeding/spreading. Together, these data suggest that TREM2-dependent activation of the DAM phenotype is essential in delaying Aβ-induced pathological tau propagation.

          Related collections

          Most cited references37

          • Record: found
          • Abstract: found
          • Article: not found

          A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease.

          Alzheimer's disease (AD) is a detrimental neurodegenerative disease with no effective treatments. Due to cellular heterogeneity, defining the roles of immune cell subsets in AD onset and progression has been challenging. Using transcriptional single-cell sorting, we comprehensively map all immune populations in wild-type and AD-transgenic (Tg-AD) mouse brains. We describe a novel microglia type associated with neurodegenerative diseases (DAM) and identify markers, spatial localization, and pathways associated with these cells. Immunohistochemical staining of mice and human brain slices shows DAM with intracellular/phagocytic Aβ particles. Single-cell analysis of DAM in Tg-AD and triggering receptor expressed on myeloid cells 2 (Trem2)(-/-) Tg-AD reveals that the DAM program is activated in a two-step process. Activation is initiated in a Trem2-independent manner that involves downregulation of microglia checkpoints, followed by activation of a Trem2-dependent program. This unique microglia-type has the potential to restrict neurodegeneration, which may have important implications for future treatment of AD and other neurodegenerative diseases. VIDEO ABSTRACT.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases

            Microglia play a pivotal role in maintenance of brain homeostasis, but lose homeostatic function during neurodegenerative disorders. We identified a specific apolipoprotein E (APOE)-dependent molecular signature in microglia from models of amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and Alzheimer’s disease (AD) and in microglia surrounding neuritic β-amyloid (Aβ) -plaques in human AD brains. The APOE pathway mediated a switch from a homeostatic to neurodegenerative microglia phenotype following phagocytosis of apoptotic neurons. Triggering receptor expressed on myeloid cells 2 (TREM2) induced APOE signaling, and targeting the TREM2-APOE pathway restored the homeostatic signature of microglia in ALS and AD mouse models and prevented neuronal loss in an acute model of neurodegeneration. APOE-mediated neurodegenerative microglia led to a loss in their tolerogenic function. Taken together, our work identifies the TREM2-APOE pathway as a major regulator of microglial functional phenotype in neurodegenerative diseases and serves as a novel target to restore homeostatic microglia. Microglia change their phenotype and function during aging and neurodegeneration, but the underlying molecular mechanisms for this change remain unknown. Krasemann, Madore, et al. identify the TREM2-APOE pathway as a major regulator of microglia phenotypic change in neurodegenerative diseases, which may serve as a target to restore homeostatic microglia.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation.

              Mutations in the genes for amyloid precursor protein (APP) and presenilins (PS1, PS2) increase production of beta-amyloid 42 (Abeta42) and cause familial Alzheimer's disease (FAD). Transgenic mice that express FAD mutant APP and PS1 overproduce Abeta42 and exhibit amyloid plaque pathology similar to that found in AD, but most transgenic models develop plaques slowly. To accelerate plaque development and investigate the effects of very high cerebral Abeta42 levels, we generated APP/PS1 double transgenic mice that coexpress five FAD mutations (5XFAD mice) and additively increase Abeta42 production. 5XFAD mice generate Abeta42 almost exclusively and rapidly accumulate massive cerebral Abeta42 levels. Amyloid deposition (and gliosis) begins at 2 months and reaches a very large burden, especially in subiculum and deep cortical layers. Intraneuronal Abeta42 accumulates in 5XFAD brain starting at 1.5 months of age (before plaques form), is aggregated (as determined by thioflavin S staining), and occurs within neuron soma and neurites. Some amyloid deposits originate within morphologically abnormal neuron soma that contain intraneuronal Abeta. Synaptic markers synaptophysin, syntaxin, and postsynaptic density-95 decrease with age in 5XFAD brain, and large pyramidal neurons in cortical layer 5 and subiculum are lost. In addition, levels of the activation subunit of cyclin-dependent kinase 5, p25, are elevated significantly at 9 months in 5XFAD brain, although an upward trend is observed by 3 months of age, before significant neurodegeneration or neuron loss. Finally, 5XFAD mice have impaired memory in the Y-maze. Thus, 5XFAD mice rapidly recapitulate major features of AD amyloid pathology and may be useful models of intraneuronal Abeta42-induced neurodegeneration and amyloid plaque formation.
                Bookmark

                Author and article information

                Contributors
                Role: ConceptualizationRole: Data curationRole: Formal analysisRole: Funding acquisitionRole: InvestigationRole: MethodologyRole: Project administrationRole: ResourcesRole: ValidationRole: VisualizationRole: Writing - original draftRole: Writing - review & editing
                Role: ConceptualizationRole: Formal analysisRole: InvestigationRole: MethodologyRole: ValidationRole: Writing - original draft
                Role: InvestigationRole: ValidationRole: Writing - review & editing
                Role: Data curationRole: InvestigationRole: SoftwareRole: ValidationRole: VisualizationRole: Writing - review & editing
                Role: InvestigationRole: ResourcesRole: Writing - review & editing
                Role: Investigation
                Role: Methodology
                Role: ConceptualizationRole: Funding acquisitionRole: SupervisionRole: Writing - original draftRole: Writing - review & editing
                Role: ConceptualizationRole: Formal analysisRole: Funding acquisitionRole: MethodologyRole: Project administrationRole: ResourcesRole: SupervisionRole: ValidationRole: VisualizationRole: Writing - original draftRole: Writing - review & editing
                Journal
                J Exp Med
                J Exp Med
                jem
                The Journal of Experimental Medicine
                Rockefeller University Press
                0022-1007
                1540-9538
                02 August 2021
                08 June 2021
                : 218
                : 8
                : e20210542
                Affiliations
                [1 ] Department of Neurology, Washington University School of Medicine, St. Louis, MO
                [2 ] Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO
                [3 ] Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO
                [4 ] Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, St. Louis, MO
                Author notes
                Correspondence to David M. Holtzman: holtzman@ 123456wustl.edu

                Disclosures: M. Colonna reported "other" from Vigil Neuroscience, and grants from Ono and Pfizer outside the submitted work; in addition, M. Colonna had a patent to TREM2 pending. J.D. Ulrich reported a patent to anti-TREM2 agonist antibodies pending. D.M. Holtzman reported grants from NIH, JPB Foundation, Charles and Helen Schwab Foundation, and Edward N. and Della L. Thome Memorial Foundation during the conduct of the study; "other" from C2N Diagnostics; and personal fees from Denali, Genentech, Merck, Cajal Neurosciences, and Takeda outside the submitted work; in addition, D.M. Holtzman had a patent to anti-tau antibodies licensed and a provisional patent on anti-TREM2 antibodies pending. No other disclosures were reported.

                Author information
                https://orcid.org/0000-0002-1552-8815
                https://orcid.org/0000-0003-0547-9463
                https://orcid.org/0000-0001-5807-190X
                https://orcid.org/0000-0001-5360-5466
                https://orcid.org/0000-0002-3899-5651
                https://orcid.org/0000-0002-5937-0212
                https://orcid.org/0000-0001-5222-4987
                https://orcid.org/0000-0002-4743-926X
                https://orcid.org/0000-0002-3400-0856
                Article
                jem.20210542
                10.1084/jem.20210542
                8190588
                34100905
                9f335394-90cd-4853-9403-92008fb197c3
                © 2021 Gratuze et al.

                This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

                History
                : 06 March 2021
                : 22 April 2021
                : 12 May 2021
                Page count
                Pages: 11
                Funding
                Funded by: BrightFocus Foundation, DOI http://dx.doi.org/10.13039/100006312;
                Award ID: A2020257F
                Funded by: National Institutes of Health, DOI http://dx.doi.org/10.13039/100000002;
                Award ID: AG047644
                Award ID: UL1 TR000448
                Funded by: JPB Foundation, DOI http://dx.doi.org/10.13039/100007457;
                Funded by: Charles and Helen Schwab Foundation;
                Funded by: Edward N. and Della L. Thome Memorial Foundation, DOI http://dx.doi.org/10.13039/100008097;
                Funded by: NIH Office of the Director, DOI http://dx.doi.org/10.13039/100000002;
                Award ID: OD021629
                Funded by: Washington University School of Medicine, DOI http://dx.doi.org/10.13039/100011912;
                Funded by: Children’s Discovery Institute of Washington University;
                Funded by: St. Louis Children’s Hospital;
                Award ID: CDI-CORE-2015-505
                Award ID: CDI-CORE-2019-813
                Funded by: Foundation for Barnes-Jewish Hospital, DOI http://dx.doi.org/10.13039/100007338;
                Award ID: 3770
                Award ID: 4642
                Funded by: National Cancer Institute, DOI http://dx.doi.org/10.13039/100000054;
                Award ID: P30 CA91842
                Funded by: National Center for Research Resources, DOI http://dx.doi.org/10.13039/100000097;
                Categories
                Brief Definitive Report
                Neuroinflammation

                Medicine
                Medicine

                Comments

                Comment on this article